Preformed Albumin-Paclitaxel/Anti-VEGF Complexes for Melanoma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for melanoma, a serious form of skin cancer, are inadequate in prolonging progression-free survival and often result in significant toxicity, with existing chemotherapies failing to effectively target vascular endothelial growth factor (VEGF) pathways.

Innovation Solution

The use of preformed nanoparticle complexes comprising albumin-bound paclitaxel (Abraxane®) and anti-VEGF antibodies (Avastin®) to form macromolecular complexes that enhance tumor cell cytotoxicity while maintaining target binding specificity, administered either systemically or intratumorally, with customizable size and composition to optimize treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapies are used to treat melanoma, then tumor cells are targeted, but progression-free survival is not significantly prolonged and significant toxicity occurs

Engineering Contradiction:

Improveprogression-free survivalVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines albumin-bound paclitaxel nanoparticles with anti-VEGF antibodies into a single preformed complex, merging chemotherapy and anti-angiogenic therapy into one unified treatment agent that simultaneously delivers both therapeutic mechanisms to the tumor

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite nanomedicine structure consisting of albumin nanoparticles bound to paclitaxel and further complexed with anti-VEGF antibodies, forming a multi-component composite material that integrates multiple therapeutic functions

Inventive Principle:

Principle #40Composite materials

2Reliability

If existing chemotherapies are administered, then treatment is provided, but they fail to effectively target VEGF pathways

Engineering Contradiction:

Improvetarget binding specificityVSAvoidmulti-target capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The preformed complex serves multiple functions simultaneously: it delivers chemotherapeutic paclitaxel to tumor cells while also binding to VEGF to inhibit angiogenesis, making a single agent that performs both chemotherapy and anti-angiogenic therapy

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If nanoparticle complexes are formed with customizable size and composition, then treatment efficacy is optimized, but formulation complexity increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent prepares preformed complexes of albumin-bound paclitaxel and anti-VEGF antibodies in advance, allowing optimization of complex formation conditions, size distribution, and composition before clinical administration, thereby simplifying the actual treatment process

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12364754B2Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab

Publication Date: 2025.07.22 MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

AI summary

Disclosed herein are compositions comprising nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25. Additionally disclosed herein are methods using the compositions of the present invention, such as for treating a VEGF-expressing cancer in a mammal, for example, skin cancer.